PSTV
Plus Therapeutics·NASDAQ
--
--(--)
--
--(--)
8.46 / 10
Outperform
PSTV's fundamentals are exceptional (8.5/10). Key strengths include high current and fixed assets turnover ratios, indicating efficient asset utilization. Although gross profit margin is theoretically 100%, practical interpretation warrants caution. Inventory turnover is also favorable at 34.28, reflecting effective inventory management. These metrics collectively place the stock in a strong fundamental position despite recent dilution from a $15 million offering.
Analysis Checks(3/4)
Inventory turnover ratio
Value34.28
Score2/3
Weight-190.40%
1M Return-2.37%
Value34.28
Score2/3
Weight-190.40%
1M Return-2.37%
Current assets turnover ratio
Value0.01
Score2/3
Weight147.47%
1M Return1.75%
Value0.01
Score2/3
Weight147.47%
1M Return1.75%
Gross profit margin (%)
Value100.00
Score1/3
Weight17.13%
1M Return0.22%
Value100.00
Score1/3
Weight17.13%
1M Return0.22%
Fixed assets turnover ratio
Value0.16
Score3/3
Weight125.80%
1M Return1.53%
Value0.16
Score3/3
Weight125.80%
1M Return1.53%
Inventory turnover ratio
Value34.28
Score2/3
Weight-190.40%
1M Return-2.37%
Value34.28
Score2/3
Weight-190.40%
1M Return-2.37%
Gross profit margin (%)
Value100.00
Score1/3
Weight17.13%
1M Return0.22%
Value100.00
Score1/3
Weight17.13%
1M Return0.22%
Current assets turnover ratio
Value0.01
Score2/3
Weight147.47%
1M Return1.75%
Value0.01
Score2/3
Weight147.47%
1M Return1.75%
Fixed assets turnover ratio
Value0.16
Score3/3
Weight125.80%
1M Return1.53%
Value0.16
Score3/3
Weight125.80%
1M Return1.53%
Is PSTV undervalued or overvalued?
- PSTV scores 8.46/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, -391.33% net margin, -2.25 P/E ratio, 9.17 P/B ratio, and 63.89% earnings growth, these metrics solidify its Outperform investment rating.
